ArticleThe Journal of pediatrics2018
Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight.
Article in The Journal of pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Fluid restriction for treatment of symptomatic patent ductus arteriosus in preterm infants.The Cochrane database of systematic reviews · 2024Pooled it
- Related Factors of Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2020Pooled it
- Furosemide for patent ductus arteriosus during cyclooxygenase inhibitor therapy: A systematic review.Pediatrics international : official journal of the Japan Pediatric SocietyPooled it
- Bartter syndrome as natural experiment if furosemide (re)opens the ductus arteriosus.Pediatric research · 2025Article
- The effect of furosemide on extremely premature infants treated with nonsteroidal anti-inflammatory drugs for persistent patent ductus arteriosus.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Furosemide and Ductus Arteriosus Closure in Very-Low-Birth-Weight Preterm Infants: A Comprehensive Retrospective Study.Children (Basel, Switzerland) · 2024Article
- Evaluation of the Closure of Patent Ductus Arteriosus With Ibuprofen Compared to Indomethacin.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants.Journal of perinatology : official journal of the California Perinatal Association · 2022Review
- Echocardiographic assessment of intimal thickness growth of patent ductus arteriosus in neonates and analysis of influencing factors.The international journal of cardiovascular imaging · 2022Article
- Insulin-like growth factor-1: A potential target for bronchopulmonary dysplasia treatment (Review).Experimental and therapeutic medicine · 2022Review
- An Update on Patent Ductus Arteriosus and What is Coming Next.Turkish archives of pediatrics · 2022Article
- Use of diuretics in the neonatal period.Pediatric nephrology (Berlin, Germany) · 2021Review
- Early Urinary Metabolomics in Patent Ductus Arteriosus Anticipates the Fate: Preliminary Data.Frontiers in pediatrics · 2020Article
- Regional tissue oxygenation monitoring in the neonatal intensive care unit: evidence for clinical strategies and future directions.Pediatric research · 2019Review
- Oral ibuprofen is superior to oral paracetamol for patent ductus arteriosus in very low and extremely low birth weight infants.Medicine · 2019Observational
- Understanding the pathobiology in patent ductus arteriosus in prematurity-beyond prostaglandins and oxygen.Pediatric research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the association between furosemide exposure and patent ductus arteriosus (PDA) in a large, contemporary cohort of hospitalized infants with very low birth weight (VLBW). STUDY
designUsing the Pediatrix Medical Group Clinical Data Warehouse, we identified all inborn infants of VLBW <37 weeks of gestation discharged from the neonatal intensive care unit after the first postnatal week from 2011 to 2015. We defined PDA as any medical (ibuprofen or indomethacin) or surgical PDA therapy. We collected data up to the day of PDA treatment or postnatal day 18 for infants not diagnosed with PDA. We performed multivariable logistic regression to evaluate the association between PDA and exposure to furosemide.
resultsWe included 43 576 infants from 337 neonatal intensive care units, of whom 6675 (15%) underwent PDA treatment. Infants with PDA were more premature and more often exposed to mechanical ventilation and inotropes. Furosemide was prescribed to 4055 (9%) infants. On multivariable regression, exposure to furosemide was associated with decreased odds of PDA treatment (OR 0.72; 95% CI 0.65-0.79). Increasing percentage of days with furosemide exposure was not associated with PDA treatment (OR 1.01; 95% CI 0.97-1.06).
conclusionsFurosemide exposure was not associated with increased odds of PDA treatment in hospitalized infants of VLBW. Further studies are needed to characterize the efficacy and safety of furosemide in premature infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.